Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

Organoid culture of bladder cancer cells.

Yoshida T, Singh AK, Bishai WR, McConkey DJ, Bivalacqua TJ.

Investig Clin Urol. 2018 May;59(3):149-151. doi: 10.4111/icu.2018.59.3.149. Epub 2018 Apr 30. No abstract available.

2.

HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells.

White MC, Schroeder RD, Zhu K, Xiong K, McConkey DJ.

Oncogene. 2018 May 3. doi: 10.1038/s41388-018-0227-y. [Epub ahead of print]

PMID:
29720726
3.

Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells.

Yoshida T, Sopko NA, Kates M, Liu X, Joice G, McConkey DJ, Bivalacqua TJ.

Oncotarget. 2018 Jan 24;9(13):11060-11070. doi: 10.18632/oncotarget.24308. eCollection 2018 Feb 16.

4.

Subtyping Bladder Cancers: Biology vs Bioinformatics.

McConkey DJ, Choi W.

J Natl Cancer Inst. 2018 May 1;110(5):439-440. doi: 10.1093/jnci/djx254. No abstract available.

PMID:
29342301
5.

Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.

Liao RS, Gupta M, Schwen ZR, Patel HD, Kates M, Johnson MH, Hahn NM, McConkey D, Bivalacqua TJ, Pierorazio PM.

J Urol. 2018 Jul;200(1):68-73. doi: 10.1016/j.juro.2017.12.054. Epub 2018 Jan 4.

PMID:
29307680
6.

Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line.

Yoshida T, Kates M, Sopko NA, Liu X, Singh AK, Bishai WR, Joice G, McConkey DJ, Bivalacqua TJ.

Urol Oncol. 2018 Apr;36(4):160.e23-160.e32. doi: 10.1016/j.urolonc.2017.11.024. Epub 2017 Dec 26.

PMID:
29288005
8.

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA.

Eur Urol. 2018 May;73(5):738-748. doi: 10.1016/j.eururo.2017.10.003. Epub 2017 Oct 18. Review.

PMID:
29055653
9.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5.

PMID:
28988769
10.

Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells.

Schroeder RD, Choi W, Hong DS, McConkey DJ.

Oncotarget. 2017 Jun 7;8(31):51675-51687. doi: 10.18632/oncotarget.18386. eCollection 2017 Aug 1.

11.

Effects of thiazolidinedione in patients with active bladder cancer.

Li R, Metcalfe MJ, Ferguson JE 3rd, Mokkapati S, Nogueras González GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM.

BJU Int. 2018 Feb;121(2):244-251. doi: 10.1111/bju.14009. Epub 2017 Sep 23.

PMID:
28872778
12.

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.

Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, Sopko NA, Matsui H, Hahn NM, McConkey DJ, Baras A, Hanes J, Ensign L, Bivalacqua TJ.

Clin Cancer Res. 2017 Nov 1;23(21):6592-6601. doi: 10.1158/1078-0432.CCR-17-1082. Epub 2017 Aug 14.

PMID:
28808039
13.

Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.

Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C.

Eur Urol Focus. 2017 Dec;3(6):577-583. doi: 10.1016/j.euf.2017.06.004. Epub 2017 Jul 13.

PMID:
28753816
14.

Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer.

Pal SK, Pham A, Vuong W, Liu X, Lin Y, Ruel N, Yuh BE, Chan K, Wilson T, Lerner SP, McConkey D, Jove R, Liang W.

Eur Urol Focus. 2017 Feb;3(1):130-135. doi: 10.1016/j.euf.2016.03.003. Epub 2016 Mar 25.

PMID:
28720358
15.

Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ.

Cancer Immunol Res. 2017 Jul;5(7):594-603. doi: 10.1158/2326-6066.CIR-16-0267. Epub 2017 Jun 6.

16.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
17.

Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP.

Eur Urol. 2017 Sep;72(3):354-365. doi: 10.1016/j.eururo.2017.03.010. Epub 2017 Mar 30. Review.

PMID:
28365159
18.

The integrated stress response and proteotoxicity in cancer therapy.

McConkey DJ.

Biochem Biophys Res Commun. 2017 Jan 15;482(3):450-453. doi: 10.1016/j.bbrc.2016.11.047. Epub 2017 Feb 3. Review.

19.

Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.

Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, Huang L, Shoshan E, Velazquez-Torres G, Nitti G, Lee S, Lee JG, Fuentes-Mattei E, Willis D, Zhang L, Guo CC, Yao H, Baggerly K, Lotan Y, Lerner SP, Dinney C, McConkey D, Bar-Eli M, Czerniak B.

Sci Rep. 2017 Jan 19;7:40714. doi: 10.1038/srep40714.

20.

Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.

Ochoa AE, Choi W, Su X, Siefker-Radtke A, Czerniak B, Dinney C, McConkey DJ.

Oncotarget. 2016 Dec 6;7(49):80164-80174. doi: 10.18632/oncotarget.13284.

21.

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.

Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B.

EBioMedicine. 2016 Oct;12:105-117. doi: 10.1016/j.ebiom.2016.08.036. Epub 2016 Aug 25.

22.

Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.

Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM.

BJU Int. 2017 May;119(5):684-691. doi: 10.1111/bju.13689. Epub 2016 Nov 11.

23.

Intrinsic subtypes and bladder cancer metastasis.

McConkey DJ, Choi W, Ochoa A, Dinney CPN.

Asian J Urol. 2016 Oct;3(4):260-267. doi: 10.1016/j.ajur.2016.09.009. Epub 2016 Sep 23. Review.

24.

Biology and therapy of urological cancer metastasis.

Posadas EM, McConkey DJ, Chung LWK.

Asian J Urol. 2016 Oct;3(4):167-169. doi: 10.1016/j.ajur.2016.09.008. Epub 2016 Sep 23. No abstract available.

25.

Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis.

Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C.

Oncotarget. 2017 May 23;8(21):34205-34222. doi: 10.18632/oncotarget.11009.

26.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

27.

Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Höglund M, Real FX.

Bladder Cancer. 2016 Jan 7;2(1):37-47.

28.

Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.

Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B.

Eur Urol. 2016 Oct;70(4):611-620. doi: 10.1016/j.eururo.2016.02.056. Epub 2016 Mar 15.

29.

Origins of Bladder Cancer.

Czerniak B, Dinney C, McConkey D.

Annu Rev Pathol. 2016 May 23;11:149-74. doi: 10.1146/annurev-pathol-012513-104703. Epub 2016 Feb 22. Review.

PMID:
26907529
30.

Targeting Signaling Transduction Pathways in Bladder Cancer.

Abbosh PH, McConkey DJ, Plimack ER.

Curr Oncol Rep. 2015 Dec;17(12):58. doi: 10.1007/s11912-015-0477-6. Review.

PMID:
26472299
31.

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.

McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO.

Eur Urol. 2016 May;69(5):855-62. doi: 10.1016/j.eururo.2015.08.034. Epub 2015 Sep 3.

32.

Bridging the Gap in Upper Tract Urothelial Carcinoma.

Matin SF, McConkey DJ.

Eur Urol. 2015 Dec;68(6):978-9. doi: 10.1016/j.eururo.2015.08.009. Epub 2015 Aug 20. No abstract available.

PMID:
26298210
33.

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA.

Eur Urol. 2015 Dec;68(6):959-67. doi: 10.1016/j.eururo.2015.07.009. Epub 2015 Aug 1.

34.

Genetic subtypes of invasive bladder cancer.

McConkey DJ, Choi W, Dinney CP.

Curr Opin Urol. 2015 Sep;25(5):449-58. doi: 10.1097/MOU.0000000000000200. Review.

PMID:
26218634
35.

Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.

McConkey DJ, Choi W, Ochoa A, Siefker-Radtke A, Czerniak B, Dinney CP.

Hematol Oncol Clin North Am. 2015 Apr;29(2):377-94, x-xi. doi: 10.1016/j.hoc.2014.11.003. Review.

PMID:
25836941
36.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24. Review.

38.

Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ.

Nat Rev Urol. 2014 Jul;11(7):400-10. doi: 10.1038/nrurol.2014.129. Epub 2014 Jun 24. Review.

PMID:
24960601
39.

Micropapillary bladder cancer: current treatment patterns and review of the literature.

Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM.

Urol Oncol. 2014 Aug;32(6):826-32. doi: 10.1016/j.urolonc.2014.01.020. Epub 2014 Jun 13. Review.

40.

New insights into subtypes of invasive bladder cancer: considerations of the clinician.

McConkey DJ, Choi W, Dinney CP.

Eur Urol. 2014 Oct;66(4):609-10. doi: 10.1016/j.eururo.2014.05.006. Epub 2014 May 27. No abstract available.

PMID:
24877661
41.

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ.

Cancer Cell. 2014 Feb 10;25(2):152-65. doi: 10.1016/j.ccr.2014.01.009.

42.

Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells.

Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ, Siefker-Radtke A.

PLoS One. 2013 Jul 18;8(7):e69509. doi: 10.1371/journal.pone.0069509. Print 2013.

43.

A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin.

Lee EK, Jinesh G G, Laing NM, Choi W, McConkey DJ, Kamat AM.

Cancer Biol Ther. 2013 Sep;14(9):812-22. doi: 10.4161/cbt.25326. Epub 2013 Jun 19.

44.

Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.

Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, Ashkenazi A, Czerniak B, Dinney CP, Black PC.

Mol Cancer Ther. 2013 Jul;12(7):1245-54. doi: 10.1158/1535-7163.MCT-12-1150. Epub 2013 May 8.

45.

Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa.

Jäger W, Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, Hadaschik BA, Matsui Y, Anderson S, Bell RH, Ettinger S, So AI, Gleave ME, Lee IL, Dinney CP, Tachibana M, McConkey DJ, Black PC.

J Urol. 2013 Oct;190(4):1404-9. doi: 10.1016/j.juro.2013.03.009. Epub 2013 Mar 7.

46.

Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.

Cheng T, Roth B, Choi W, Black PC, Dinney C, McConkey DJ.

PLoS One. 2013;8(2):e57284. doi: 10.1371/journal.pone.0057284. Epub 2013 Feb 26.

47.

In-frame cDNA library combined with protein complementation assay identifies ARL11-binding partners.

Lee S, Lee I, Jung Y, McConkey D, Czerniak B.

PLoS One. 2012;7(12):e52290. doi: 10.1371/journal.pone.0052290. Epub 2012 Dec 18.

48.

The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205.

Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, Wen S, Flores ER, Siefker-Radtke A, Czerniak B, Dinney C, Barton M, McConkey DJ.

J Biol Chem. 2013 Feb 1;288(5):3275-88. doi: 10.1074/jbc.M112.408104. Epub 2012 Dec 13.

49.

HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.

McConkey DJ, White M, Yan W.

Adv Cancer Res. 2012;116:131-63. doi: 10.1016/B978-0-12-394387-3.00004-5. Review.

PMID:
23088870
50.

Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin.

Braeuer RR, Zigler M, Kamiya T, Dobroff AS, Huang L, Choi W, McConkey DJ, Shoshan E, Mobley AK, Song R, Raz A, Bar-Eli M.

Cancer Res. 2012 Nov 15;72(22):5757-66. doi: 10.1158/0008-5472.CAN-12-2424. Epub 2012 Sep 17.

Supplemental Content

Loading ...
Support Center